Accuracy Of The Prediction Of The Distant Recurrence Risk Of Patients With Ductal Luminal Breast Cancer Based On Clinical Factors Versus Prediction Based On Oncogenic Mutations Or Gene Expression.

e12585Background: Luminal breast cancer is not a uniform cancer type, but a heterogeneous group of disease subtypes characterized by own clinical, pathologic, biologic and genetic characteristics. Traditionally clinical-pathologic (CP) variables have been used to guide the use of endocrine treatment and/or chemotherapy to inform the choice of systemic adjuvant therapy for patients with early stage breast cancer. More recently gene expression profiling of tumours has been applied to aid doctors in personalizing treatment decisions. In the retrospective study presented here we worked with ER and/or PR positive, HER2 negative ductal breast cancers of the METABRIC collection (N = 1.104) to determine the prediction accuracy (PA) of different distant recurrence risk (DDR) prediction methods used in clinical practice. Methods: CP and genomic variables (oncogenic mutations/CNV, gene expression) were used to develop a prognostic model for disease free survival using a robust statistics approach combined with cross...